Clinician's Pocket Drug Reference 2008

124 Interferon Beta-1bInterferon Beta-1b (Betaseron) Uses: *MS, relapsing/remitting/ secondaryprogressive* Action: Biologic response modifier Dose: 0.25 mg SQ qodCaution: [C, ?] Contra: Human albumin allergy Disp: Powder for inj 0.3 mg (32MU IFN) SE: Flulike synd, depression, blood dyscrasias, inj site necrosis, anaphylaxisNotes: Pt self inj, rotate sites; monitor LFTs, CBC 1, 3, 6 mo, TFT Q 6 moInterferon -1b (Actimmune) Uses: *↓ Incidence of serious Infxns inchronic granulomatous Dz (CGD), osteoporosis* Action: Biologic response modifierDose: Adults. CGD: 50 mcg/m 2 SQ (1.5 million units/m 2 ) BSA >0.5 m 2 ; ifBSA 12 y. 2–4 puffs qid, max 12 inh/day Nasal: 2 sprays/nostrilbid–tid; Nebulization 500 mcg 3–4 times/day Caution: [B, +/–] w/inhaled insulinContra: Allergy to soya lecithin/related foods Disp: HFA Met-dose inhaler 18mcg/dose; inhal soln 0.02%; nasal spray 0.03, 0.06% SE: Nervousness, dizziness,HA, cough, bitter taste, nasal dryness, URI, epistaxis Notes: Not for acute bronchospasmIrbesartan (Avapro) Uses: *HTN, DN*, CHF Action: Angiotensin II receptorantagonist Dose: 150 mg/d PO, may to 300 mg/d Caution: [C (1st tri;D 2nd/3rd), ?/–] Disp: Tabs 75, 150, 300 mg SE: Fatigue, ↓ BP ↑ KIrinotecan (Camptosar) WARNING: D and myelosuppression Uses:*Colorectal* & lung CA Action: Topoisomerase I inhibitor; ↓ DNA synth Dose:Per protocol; 125–350 mg/m 2 qwk–q3wk (↓ hepatic dysfunction, as tolerated pertox) Caution: [D, –] Contra: Allergy to component Disp: Inj 20 mg/mL SE:↓ BM, N/V/D, abd cramping, alopecia; D is dose limiting; Rx acute D w/ atropine;Rx subacute D w/ loperamide Notes: D correlated to levels of metaboliteSN-38